Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
- Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
- Bristol-Myers Italy Head Piras Sworn in as Japan President
November 21, 2013
- Shionogi Licenses 2 Oxycodone Products with Abuse-Deterrent Measures from Mundipharma
November 21, 2013
- US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
- Nichi-Iko to Collaborate with Hanoi Pharmaceutical of Vietnam
November 20, 2013
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
- CMIC Chairman Sorry for Alleged Clinical Data Tampering; Probe Report Due out Late November
November 18, 2013
- PIII Study of Brexpiprazole Starts in US and Europe for Treatment of Agitation in AD: Otsuka Holdings
November 18, 2013
- Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
- Kyowa Kirin Ceases Japan PII Trial on Chronic Kidney Disease Agent
November 13, 2013
- JV of DSP, Japan BCG to Develop New TB Vaccines with NIBIO, US NPO
November 13, 2013
- Antiepileptic Drug Eslicarbazepine Granted US Approval: DSP
November 13, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…